Drug analysis method and system, electronic equipment and storage medium

Abstract

The invention relates to the technical field of medicine analysis, particularly provides a medicine analysis method and system, electronic equipment and a storage medium, and aims to solve the technical problem that an MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization Time of Flight)-based analysis technology cannot comprehensively, quickly and accurately analyze medicines. In order to achieve the purpose, the method comprises the steps that sample information of a user is obtained; the sample information at least comprises site typing information of the user; verifying the sample information, and judging whether the sample information is valid or not; and if the sample information is valid, obtaining a drug analysis result of the user based on a drug database and a genome library corresponding to the site typing information. Through the implementation mode, the medicine can be comprehensively, quickly and accurately analyzed according to the site typing information of the user, and personalized medication guidance and suggestions are provided for the user, so that the safety and effectiveness of the medicine are improved, adverse reactions are avoided, and personalized precise medication is realized.

Description

Technical Field

[0001] The present application relates to the field of pharmaceutical analysis technology, and in particular to a drug analysis method, system, electronic device and storage medium. Background Art

[0002] In the current field of pharmaceutical analysis, the quality control of drug preparations is a key link to ensure the efficacy and safety of drugs. Although traditional drug analysis methods, such as High Performance Liquid Chromatography (HPLC), are widely used, they often have limitations when faced with complex drug structures and high sensitivity and high separation detection requirements.

[0003] As an emerging analytical method, matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF) technology has shown great potential in the field of drug analysis due to its unique advantages. However, the safe drug use analysis technology based on MALDI-TOF is still imperfect and cannot comprehensively, quickly and accurately analyze drugs, thus failing to provide users with personalized usage recommendations.

[0004] Accordingly, the art needs a new technical solution to solve the above problems. Summary of the invention

[0005] In order to overcome the above-mentioned defects, the present application is proposed to provide a drug analysis method, system, electronic device and storage medium that solves or at least partially solves the technical problem that MALDI-TOF-based analysis technology cannot comprehensively, quickly and accurately analyze drugs.

[0006] In a first aspect, a drug analysis method is provided, characterized in that the method comprises:

[0007] Acquire sample information of the user; the sample information at least includes site typing information of the user;

[0008] Verifying the sample information to determine whether the sample information is valid;

[0009] If the sample information is valid, the drug analysis result of the user is obtained based on the drug database and genome library corresponding to the site typing information.

[0010] In a technical solution of the above-mentioned drug analysis method, the sample information also includes the user's identity information and sample point information, and the site typing information includes site information and typing results; and obtaining the user's sample information includes:

[0011] Get the user's disease category;

[0012] Based on the MALDI-TOF device, obtaining sample data related to the disease category;

[0013] The sample data is parsed to obtain sample information in a preset format.

[0014] In a technical solution of the above-mentioned drug analysis method, the verifying of the sample information to determine whether the sample information is valid includes:

[0015] Determine whether the sample information has at least one of missing information, incorrect site information, repeated site information, and incorrect typing results;

[0016] If so, the sample information is determined to be invalid; otherwise, the sample information is determined to be valid.

[0017] In a technical solution of the above-mentioned drug analysis method, the method further comprises:

[0018] Determine a drug database corresponding to the site typing information based on the disease type;

[0019] The drug database corresponding to the site typing information includes drugs related to the disease category, the effect of each drug on the site information and expert advice.

[0020] In a technical solution of the above-mentioned drug analysis method, the genome library includes the relationship between the drug in the drug database and the site information; the drug analysis result of the user obtained based on the drug database and the genome library corresponding to the site typing information includes:

[0021] Screening the drug database and the genome library corresponding to the site typing information to obtain the drug corresponding to the site typing information;

[0022] Based on the effect of the drug on the site information and the expert advice, the drug is analyzed to obtain a drug analysis result for the user.

[0023] In a technical solution of the above-mentioned drug analysis method, the drug analysis result of the user includes the analysis result and / or expert advice on the effects of different drugs on the user and / or the dosage of the drugs; after obtaining the drug analysis result of the user, the method further includes:

[0024] Get report templates for drug analysis;

[0025] Filling the drug analysis results into the report template to obtain a drug analysis report;

[0026] The report templates include preset report templates and customized report templates. In a technical solution of the above-mentioned drug analysis method, the method further comprises:

[0027] If the sample information is invalid, an error message is issued and the drug analysis process ends.

[0028] In a second aspect, the present application provides a drug analysis system, characterized in that the system comprises:

[0029] An acquisition module, configured to acquire sample information of a user; the sample information at least includes site typing information of the user;

[0030] A verification module, configured to verify the sample information and determine whether the sample information is valid;

[0031] The analysis module is configured to obtain the user's drug analysis results based on the drug database and genome library corresponding to the site typing information if the sample information is valid.

[0032] In a third aspect, an electronic device is provided, which includes a processor and a memory, wherein the memory is suitable for storing multiple program codes, and the program codes are suitable for being loaded and run by the processor to execute the drug analysis method described in any one of the technical solutions of the above-mentioned drug analysis method.

[0033] In a fourth aspect, a computer-readable storage medium is provided, in which a plurality of program codes are stored, wherein the program codes are suitable for being loaded and run by a processor to execute the drug analysis method described in any one of the technical solutions of the above-mentioned drug analysis method.

[0034] The above one or more technical solutions of this application have at least one or more of the following Beneficial effects:

[0035] In implementing the technical solution of this application, the user's sample information is first obtained, wherein the sample information at least includes the user's site typing information; then the sample information is verified to determine whether the sample information is valid; if the sample information is valid, the user's drug analysis results are obtained based on the drug database and genome library corresponding to the site typing information. Through the above implementation, the drug can be analyzed comprehensively, quickly and accurately according to the user's site typing information, and personalized medication guidance and suggestions can be provided to the user, thereby improving the safety and effectiveness of the drug, avoiding adverse reactions, and realizing personalized precision medication. It is easy to operate and can be promoted and applied in the fields of drug analysis, personalized medical research and development, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The disclosure of the present application will become easier to understand with reference to the accompanying drawings. It is easy for those skilled in the art to understand that these drawings are only for illustrative purposes and are not intended to limit the scope of protection of the present application. Among them:

[0037] Figure 1 It is a schematic flow chart of the main steps of a drug analysis method according to an embodiment of the present application;

[0038] Figure 2 This is a flowchart of the main steps of obtaining sample information of a user according to an embodiment of the present application;

[0039] Figure 3 is a schematic diagram of a drug database and a genome library according to an embodiment of the present application;

[0040] Figure 4 This is a flow chart of the main steps of obtaining a user's drug analysis result based on a drug database and a genome library corresponding to site typing information according to an embodiment of the present application;

[0041] Figure 5 is a schematic diagram of the main process of a drug analysis method according to an embodiment of the present application;

[0042] Figure 6 is a main structural block diagram of a drug analysis system according to an embodiment of the present application;

[0043] Figure 7 It is a schematic diagram of the main structure of an electronic device according to an embodiment of the present application.

[0044] List of reference numerals:

[0045] 601: acquisition module; 602: verification module; 603: analysis module; 701: processor; 702: memory. DETAILED DESCRIPTION

[0046] Some embodiments of the present application are described below with reference to the accompanying drawings. Those skilled in the art should understand that these embodiments are only used to explain the technical principles of the present application and are not intended to limit the protection scope of the present application.

[0047] In the description of the present application, "module" and "processor" may include hardware, software or a combination of the two. A module may include hardware circuits, various suitable sensors, communication ports, memory, and may also include software parts, such as program code, or a combination of software and hardware. The processor may be a central processing unit, a microprocessor, an image processor, a digital signal processor or any other suitable processor. The processor has data and / or signal processing functions. The processor may be implemented in software, hardware or a combination of the two. Non-temporary computer-readable storage media include any suitable medium that can store program code, such as a disk, a hard disk, an optical disk, a flash memory, a read-only memory, a random access memory, etc. The term "A and / or B" means all possible combinations of A and B, such as only A, only B or A and B. The term "at least one A or B" or "at least one of A and B" has a similar meaning to "A and / or B" and may include only A, only B or A and B. The singular terms "one" and "the" may also include plural forms.

[0048] Here we first explain some terms involved in this application.

[0049] MALDI-TOF: It is an important mass spectrometry analysis technology that can be used to detect and identify peptides, proteins, polysaccharides, nucleotides, glycoproteins, polymers and a variety of synthetic polymers. Its principle is that when a laser of a certain intensity is used to irradiate the co-crystallized film formed by the sample and the matrix, the matrix absorbs energy from the laser, and charge transfer occurs between the matrix and the sample, causing the sample molecules to be ionized. The ionized sample is accelerated under the action of the electric field to fly through the flight pipe and is detected according to the different flight times to the detector, that is, the mass-to-charge ratio of the ion is proportional to the flight time of the ion to detect the ion. The core technology of MALDI-TOF is to detect based on the different mass-to-charge ratios (m / z) of the sample and measure the molecular weight of the sample molecules.

[0050] Site typing information: refers to the information that classifies the genetic characteristics of an individual at a specific gene locus.

[0051] As described in the background art, in the current field of pharmaceutical analysis, quality control of drug preparations is a key link in ensuring drug efficacy and safety.

[0052] Traditional drug analysis methods, such as HPLC, have the advantages of high separation efficiency, fast analysis speed, and high detection sensitivity. They are currently the preferred method for drug impurity detection. However, for some impurities with similar structures and similar polarities, the separation degree of HPLC may be insufficient, resulting in inaccurate detection results. In addition, the operation of HPLC is relatively complex and requires high technical skills of operators. Other chromatographic techniques, such as gas chromatography (GC), are suitable for the detection of volatile impurities, but are powerless for non-volatile impurities; supercritical fluid chromatography (SFC) has the advantages of being green and environmentally friendly and having high separation efficiency, but in practical applications it is limited by the complexity and cost of equipment.

[0053] In addition, other analytical methods, such as ultraviolet spectrophotometry (UV), are easy to operate but have low sensitivity and are usually used as auxiliary means in preliminary screening or quantitative analysis; infrared spectroscopy (IR) is mainly used for structural identification of substances, but has limitations in quantitative analysis.

[0054] As an emerging analytical method, MALDI-TOF technology has shown great potential in the field of drug analysis with its unique advantages. However, the safe drug use analysis technology based on MALDI-TOF is still imperfect and cannot comprehensively, quickly and accurately analyze the various components in drug preparations, thus failing to provide users with personalized usage recommendations.

[0055] In order to solve the above problems, the present application provides a drug analysis method, system, electronic device and storage medium.

[0056] See attached Figure 1 , Figure 1 FIG. 1 is a flow chart of the main steps of a drug analysis method according to an embodiment of the present application, which is applied to a drug analysis system. Figure 1 As shown, the drug analysis method in the embodiment of the present application mainly includes the following steps S101 to S103.

[0057] Step S101: Obtain user sample information;

[0058] The sample information at least includes the user's site typing information.

[0059] Step S102: verifying the sample information to determine whether the sample information is valid;

[0060] Further, if the sample information is valid, step S103 is executed; otherwise, the drug analysis method is terminated.

[0061] Step S103: Obtain the user's drug analysis results based on the drug database and genome library corresponding to the site typing information.

[0062] Based on the method described in steps S101 to S103 above, the drug can be analyzed comprehensively, quickly and accurately according to the user's site typing information, and personalized medication guidance and suggestions can be provided to the user, thereby improving the safety and effectiveness of the drug, avoiding adverse reactions, and achieving personalized precision medication. The method is easy to operate and can be promoted and applied in the fields of drug analysis, personalized medical research and development, etc.

[0063] The above steps S101 to S103 are further explained below.

[0064] In some implementations of the above step S101, see the attached Figure 2 , Figure 2 FIG. 1 is a flow chart of the main steps of obtaining sample information of a user according to an embodiment of the present application. Figure 2 As shown, step S101 mainly includes the following steps S1011 to S1013.

[0065] Step S1011: Obtain the disease category of the user;

[0066] Generally speaking, the occurrence of different diseases is often caused by different related genes, so the user's disease category can be obtained, such as mental illness, children's disease, blood disease, etc.

[0067] Step S1012: Acquire sample data related to disease categories based on MALDI-TOF equipment;

[0068] Specifically, the user's blood (plasma or serum), urine, cerebrospinal fluid and other samples can be processed by a MALDI-TOF mass spectrometer to obtain sample data with site typing information related to the disease category.

[0069] Step S1013: parse the sample data to obtain sample information in a preset format.

[0070] In some embodiments, after the user's sample data is obtained through the MALDI-TOF device, the client of the drug analysis system corresponding to the disease category, such as a mental illness drug analysis system, a children's disease drug analysis system, a blood disease drug analysis system, etc., can be used to transmit the sample data to the server of the drug analysis system through a network (including the Internet, an intranet, a dedicated network, a wired or wireless local area network, and a wired or wireless wide area network, etc.), and the sample data is parsed by the server. The server can parse sample data related to multiple diseases at the same time.

[0071] Specifically, the server of the drug analysis system can parse sample data in various formats such as Excel, CSV, XML, JSON, etc. to obtain sample information in a preset format. Parsing sample data in various formats into a preset format can facilitate subsequent data processing and analysis.

[0072] The sample information includes the user's identity information, sample point information and site typing information.

[0073] Furthermore, the user's identity information may include the user's barcode information (such as user ID, name, etc.), gender information, age information, etc. The sample point information may include a sample location identifier, which represents a specific location on the plate. The site typing information may include site information and typing results. Among them, the site information mainly involves the location and related characteristics of a specific gene in the genome, and the typing result is a classification and description of different types of variation of a specific gene. For example, single nucleotide polymorphism (SNP) is one of the most common types of genetic variation, which refers to DNA sequence polymorphism caused by the variation of a single nucleotide at the genome level. Since DNA is composed of multiple bases such as adenine (A), guanine (G), cytosine (C) and thymine (T), the typing results of SNP include A, G, C, T, etc., and the two common allele types include A / G, C / T, A / C, etc. In addition, there may also be deletion alleles, such as del / A, which means that one chromosome is deleted and the corresponding allele of the other chromosome is A; del / G, which means that one chromosome is deleted and the corresponding allele of the other chromosome is G; and del / del, which means that both chromosomes are deleted at this site.

[0074] In some implementations, the sample data may also include sample type, sampling time, and the user's medical record information, such as medical record number, bed number, department, etc., which are not limited here.

[0075] For example, the sample data of Mr. Zhang who suffers from a blood disease is analyzed, and the obtained sample information can be shown in Table 1 below.

[0076] Table 1

[0077] Among them, there are 9 loci related to blood diseases in Zhang's genes, and the locus information and typing results are shown in Table 1.

[0078] Furthermore, in some embodiments, the analyzed sample information may also include relevant information of each site information, such as the area, mass, and signal-to-noise ratio of the mass spectrum peak corresponding to each site and its extension point.

[0079] In genetic testing, specific extension reactions are often performed. This extension reaction is usually based on a known nucleic acid sequence and further determines the information of the gene site by adding specific nucleotides. For example, when detecting SNP sites, specific primers can be designed to bind to the sequence near the site to be detected, and then the nucleotides are extended at the end of the primer to obtain the extension point of the SNP site. The extension point represents the location where the extension reaction occurs on the specific gene site in the mass spectrum.

[0080] For example, by analyzing the sample data of user Zhang who suffers from a blood disease, the relevant information of each site information obtained can be shown in Table 2 below.

[0081] Table 2

[0082] As shown in Table 2, it includes the mass spectrum peak area of ​​each site and its extension point, the mass corresponding to the ordinate of the highest point of the mass spectrum peak of each site and its extension point, and the ratio of the mass spectrum peak signal to noise (i.e., the signal-to-noise ratio) of each site and its extension point.

[0083] It should be pointed out that the above examples of user sample information are only for illustrative purposes. In actual applications, the sample information may also include the user's case information, and the relevant information of each site information may also include information of more extended points. Those skilled in the art may obtain corresponding sample information according to specific needs, which is not limited here.

[0084] The above is a further description of step S101 , and the following is a further description of step S102 .

[0085] In some implementations of the above step S102, the analyzed sample data may be verified to determine whether the sample information has missing information, incorrect site information, repeated site information, incorrect typing results, etc.

[0086] Specifically, missing information includes missing user identity information, sample point information, locus information, typing results, etc. When the locus information and typing results are wrong, the parsed locus information and typing results may be wrongly coded; when the locus information is repeated, multiple identical locus information may be parsed, such as rs100001 appears twice, and its typing results correspond to A and G respectively.

[0087] Furthermore, if the sample information contains at least one of missing information, incorrect site information, repeated site information, and incorrect typing results, the sample information is determined to be invalid. At this time, an error prompt may be issued and the drug analysis process is terminated.

[0088] If the sample information does not contain missing information, incorrect site information, repeated site information, incorrect typing results, etc., the sample information is determined to be valid, and step S103 is executed.

[0089] In some implementations of the above step S103, the drug database corresponding to the site typing information may be determined based on the disease type.

[0090] Such as the drug database corresponding to mental illness, the drug database corresponding to children's diseases, the drug database corresponding to blood diseases, etc.

[0091] See attached Figure 3 , Figure 3 It is a schematic diagram of a drug database and a genome library according to an embodiment of the present application.

[0092] like Figure 3 As shown, the drug database corresponding to the site typing information includes drugs related to disease categories, the effects of each drug on site information and expert recommendations, and may also include application types, etc.

[0093] For example, the drug database corresponding to mental illness may include drugs for mental illness such as amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, venlafaxine, mirtazapine, agomelatine, etc., as well as the effect of each drug on site information, such as drug A is more effective for users carrying a specific gene site, but has poor effects or even produces adverse reactions for other users. The effect of each drug on site information can be obtained from the genome library.

[0094] Expert advice includes personalized medication recommendations based on the effect of drugs on site information and the specific situation of the user, such as recommending specific targeted drugs for users with specific gene sites. In addition, expert advice also includes experts evaluating the efficacy and risks of drugs based on the user's gene site information, adjusting drug dosage or usage cycle. For example, for users with low drug metabolizing enzyme activity, experts may recommend reducing drug dosage to avoid drug accumulation and adverse reactions.

[0095] Application type means that drugs are classified into different application types according to their effects on site information. Each drug in the drug database has its specific site information effect and application scenario.

[0096] Furthermore, if Figure 3 As shown, the genomic library includes loci and genotypes, wherein the loci are the specific positions of genes in the genome, and the loci determine different genotypes.

[0097] Specifically, the genome library includes the relationship between drugs and site information in the drug database, such as the relationship between drug efficacy and site information, the relationship between drug adverse reactions and site information, and the relationship between drug dosage and site information. The specific storage form can be a drug and site information correspondence table. Through the drug and site information correspondence table, the effect of each drug in the drug database on the site information can be obtained.

[0098] Further, in some implementations of step S103, see the attached Figure 4 , Figure 4 This is a flow chart of the main steps of obtaining the drug analysis results of the user based on the drug database and genome library corresponding to the site typing information according to an embodiment of the present application. Figure 4 As shown, step S103 mainly includes the following steps S1031 to S1032.

[0099] Step S1031: Screening the drug database and genome library corresponding to the site typing information to obtain the drug corresponding to the site typing information;

[0100] Specifically, the user's site typing information can be compared with the information in the drug database and the genome library, and effective drugs can be screened out based on the user's site typing results.

[0101] Step S1032: Based on the effect of the drug on the site information and the expert's advice, the drug is analyzed to obtain the user's drug analysis result.

[0102] Specifically, the screened drugs can be summarized according to the effects of the drugs on the site information and expert advice to obtain the final analysis results.

[0103] The drug analysis results of the user may include analysis results and / or expert advice on the effects of different drugs on the user and / or the dosage of the drugs.

[0104] For example, for user Zhang, drug A has a better response, and it is recommended to use the recommended dosage; drug B has a poor response, and the risk of side effects may increase, so it is recommended to use it with caution; drug C has a better response, and the risk of increased fasting blood glucose concentration increases, so it is recommended to reduce the dosage (use 65% of the recommended dosage).

[0105] Furthermore, after obtaining the drug analysis result of the user, a report template for the drug analysis may be obtained, and the drug analysis result may be filled into the report template to obtain a drug analysis report.

[0106] The report template includes a preset report template and a customized report template. The preset report template is a default template, and the customized report template is a custom template. Specifically, it can be determined whether the report template is a customized report template. If so, a customized report is generated, otherwise a default report is generated, and finally the report is output.

[0107] The above is a further description of step S103.

[0108] In some embodiments, see Appendix Figure 5 , Figure 5 It is a schematic diagram of the main process of a drug analysis method according to an embodiment of the present application.

[0109] like Figure 5 As shown, the user's blood (plasma or serum), urine, cerebrospinal fluid and other samples are processed by MALDI-TOF mass spectrometry equipment to obtain sample data with site typing information related to the disease category;

[0110] Use the client of the drug analysis system corresponding to the disease category, including the mental illness drug analysis system, the children's disease drug analysis system, the blood disease drug analysis system, etc. to transmit the sample data to the server of the drug analysis system through the network;

[0111] Furthermore, the sample data can be parsed on the server side of the drug analysis system to obtain sample information and verify the sample information. When the sample information is valid, the user's drug analysis results can be obtained based on the drug database and genome library corresponding to the site typing information. Finally, the drug analysis results can be filled into the report template to obtain a drug analysis report.

[0112] Through the above implementation, the safety of medication can be improved, that is, through gene locus typing analysis, the patient's drug metabolism ability can be accurately evaluated to avoid the occurrence of adverse drug reactions. At the same time, it can enhance the effectiveness of medication, provide personalized medication recommendations based on the patient's genetic characteristics, and improve the pertinence and effectiveness of drug treatment. It can also promote the development of personalized medicine and provide strong support for precision medicine.

[0113] It should be pointed out that although the various steps in the above embodiments are described in a specific order, those skilled in the art can understand that in order to achieve the effect of the present application, different steps do not have to be executed in such an order. They can be executed simultaneously (in parallel) or in other orders. These changes are within the scope of protection of the present application.

[0114] Furthermore, the present application also provides a drug analysis system.

[0115] See attached Figure 6 , Figure 6FIG. 1 is a main structural block diagram of a drug analysis system according to an embodiment of the present application. Figure 6 As shown, the drug analysis system in the embodiment of the present application mainly includes an acquisition module 601, a verification module 602 and an analysis module 603.

[0116] In some embodiments, the acquisition module 601 can be configured to obtain the user's sample information; wherein the sample information includes at least the user's site typing information. The verification module 602 can be configured to verify the sample information and determine whether the sample information is valid. The analysis module 603 can be configured to obtain the user's drug analysis results based on the drug database and genome library corresponding to the site typing information if the sample information is valid. In one embodiment, the description of the specific implementation function can be found in steps S101 to S103.

[0117] Further, it should be understood that since the setting of each module is only for illustrating the functional units of the device of the present application, the physical devices corresponding to these modules may be the processor itself, or a part of the software in the processor, a part of the hardware, or a part of the combination of software and hardware. Therefore, the number of each module in the figure is only schematic.

[0118] It is understood by those skilled in the art that each module in the device can be adaptively split or merged. Such splitting or merging of specific modules will not cause the technical solution to deviate from the principle of the present application, and therefore, the technical solutions after splitting or merging will fall within the protection scope of the present application.

[0119] The above-mentioned drug analysis system can be used to perform Figure 1 The embodiments of the drug analysis method shown in the figure are similar in their technical principles, technical problems solved and technical effects produced. Technical personnel in this technical field can clearly understand that for the convenience and conciseness of description, the specific working process and related instructions of the drug analysis system can refer to the contents described in the embodiments of the drug analysis method, which will not be repeated here.

[0120] It is understood by those skilled in the art that all or part of the processes in the method for implementing the above-mentioned embodiment of the present application can also be completed by instructing the relevant hardware through a computer program, and the computer program can be stored in a computer-readable storage medium, and the computer program can implement the steps of the above-mentioned various method embodiments when executed by the processor. Among them, the computer program includes computer program code, and the computer program code can be in source code form, object code form, executable file or some intermediate form. The computer-readable storage medium may include: any entity or device, medium, U disk, mobile hard disk, disk, optical disk, computer memory, read-only memory, random access memory, electrical carrier signal, telecommunication signal and software distribution medium, etc. that can carry the computer program code.

[0121] Furthermore, the present application also provides an electronic device. Figure 7 , Figure 7 Schematic diagram of the main structure of an electronic device according to an embodiment of the present application. Figure 7 As shown, the electronic device in the embodiment of the present application mainly includes a processor 701 and a memory 702. The memory 702 can be configured to store a program for executing the drug analysis method of the above method embodiment, and the processor 701 can be configured to execute the program in the memory 702, which includes but is not limited to the program for executing the drug analysis method of the above method embodiment. For ease of explanation, only the part related to the embodiment of the present application is shown. For specific technical details not disclosed, please refer to the method part of the embodiment of the present application.

[0122] In some possible implementations of the present application, the electronic device may include multiple processors 701 and multiple memories 702. The program for executing the drug analysis method of the above method embodiment may be divided into multiple subprograms, each of which may be loaded and run by the processor 701 to execute different steps of the drug analysis method of the above method embodiment. Specifically, each subprogram may be stored in different memories 702, and each processor 701 may be configured to execute the program in one or more memories 702 to jointly implement the drug analysis method of the above method embodiment, that is, each processor 701 executes different steps of the drug analysis method of the above method embodiment to jointly implement the drug analysis method of the above method embodiment.

[0123] The above-mentioned multiple processors 701 may be processors deployed on the same device. For example, the above-mentioned electronic device may be a high-performance device composed of multiple processors, and the above-mentioned multiple processors 701 may be processors configured on the high-performance device. In addition, the above-mentioned multiple processors 701 may also be processors deployed on different devices. For example, the above-mentioned electronic device may be a server cluster, and the above-mentioned multiple processors 701 may be processors on different servers in the server cluster.

[0124] Further, the present application also provides a computer-readable storage medium. In a computer-readable storage medium embodiment according to the present application, the computer-readable storage medium can be configured to store a program for executing the drug analysis method of the above-mentioned method embodiment, and the program can be loaded and run by the processor to implement the above-mentioned drug analysis method. For ease of explanation, only the parts related to the embodiment of the present application are shown. For specific technical details not disclosed, please refer to the method part of the embodiment of the present application. The computer-readable storage medium can be a memory device formed by various electronic devices. Optionally, the computer-readable storage medium in the embodiment of the present application is a non-temporary computer-readable storage medium.

[0125] It should be noted that the relevant user personal information that may be involved in the various embodiments of the present application is strictly in accordance with the requirements of laws and regulations, following the principles of legality, legitimacy and necessity, based on the reasonable purposes of business scenarios, to process the personal information that users actively provide during the use of products / services or generated due to the use of products / services, as well as the personal information obtained with the user's authorization.

[0126] The user personal information processed by this application will vary depending on the specific product / service scenario, and shall be based on the specific scenario in which the user uses the product / service, and may involve the user's account information, device information or other related information. This application will treat the user's personal information and its processing with a high degree of diligence.

[0127] This application attaches great importance to the security of user personal information and has taken reasonable and feasible security protection measures that meet industry standards to protect user information and prevent personal information from being accessed, disclosed, used, modified, damaged or lost without authorization.

[0128] So far, the technical solution of the present application has been described in conjunction with an embodiment shown in the accompanying drawings, but it is easy for those skilled in the art to understand that the protection scope of the present application is obviously not limited to these specific embodiments. Without departing from the principles of the present application, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will fall within the protection scope of the present application.

Claims

1. A drug analysis method, characterized in that: The method comprises: Acquire sample information of the user; the sample information at least includes site typing information of the user; Verifying the sample information to determine whether the sample information is valid; If the sample information is valid, the drug analysis result of the user is obtained based on the drug database and genome library corresponding to the site typing information.

2. The drug analysis method according to claim 1, characterized in that: The sample information also includes the user's identity information and sample point information, and the site typing information includes site information and typing results; the method of obtaining the user's sample information includes: Get the user's disease category; Based on the MALDI-TOF device, obtaining sample data related to the disease category; The sample data is parsed to obtain sample information in a preset format.

3. The drug analysis method according to claim 2, characterized in that: The verifying the sample information to determine whether the sample information is valid includes: Determine whether the sample information has at least one of missing information, incorrect site information, repeated site information, and incorrect typing results; If so, the sample information is determined to be invalid; otherwise, the sample information is determined to be valid.

4. The drug analysis method according to claim 2, characterized in that: The method further comprises: Determine a drug database corresponding to the site typing information based on the disease type; The drug database corresponding to the site typing information includes drugs related to the disease category, the effect of each drug on the site information and expert advice.

5. The drug analysis method according to claim 4, characterized in that: The genome library includes the relationship between the drug in the drug database and the site information; The obtaining of the user's drug analysis results based on the drug database and genome library corresponding to the site typing information includes: Screening the drug database and the genome library corresponding to the site typing information to obtain the drug corresponding to the site typing information; Based on the effect of the drug on the site information and the expert advice, the drug is analyzed to obtain a drug analysis result for the user.

6. The drug analysis method according to claim 1, characterized in that: The user's drug analysis results include analysis results and / or expert advice on the effects of different drugs on the user and / or the dosage of the drugs; After obtaining the drug analysis result of the user, the method further includes: Get report templates for drug analysis; Filling the drug analysis results into the report template to obtain a drug analysis report; The report templates include preset report templates and customized report templates.

7. The drug analysis method according to claim 1, characterized in that: The method further comprises: If the sample information is invalid, an error message is issued and the drug analysis process ends.

8. A drug analysis system, characterized in that: The system comprises: An acquisition module, configured to acquire sample information of a user; the sample information at least includes site typing information of the user; A verification module, configured to verify the sample information and determine whether the sample information is valid; The analysis module is configured to obtain the user's drug analysis results based on the drug database and genome library corresponding to the site typing information if the sample information is valid.

9. An electronic device, comprising a processor and a memory, wherein the memory is suitable for storing a plurality of program codes, characterized in that: The program code is suitable for being loaded and run by the processor to execute the drug analysis method according to any one of claims 1 to 7.

10. A computer-readable storage medium storing a plurality of program codes, characterized in that: The program code is suitable for being loaded and run by a processor to execute the drug analysis method according to any one of claims 1 to 7.

Images